BioSpace News Archive

Terns Pharmaceuticals, Inc. announced the presentation of new clinical data on an improved tablet formulation of its liver-distributed farnesoid X receptor agonist TERN-101 at the Paris NASH Digital Experience, taking place virtually October 22-23, 2020.

IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced important commercial milestones from the launch of its IRRAflow system in Germany.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 per share.

Alligator Bioscience announced the decision to focus its resources on the two proprietary candidate drugs, ATOR-1017 and mitazalimab.

Round led by PureosBioventures with new and existing investors, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq

First-in-human phase 1 study to evaluate DS-1055 as a new type of immune intervention for patients with relapsed/refractory advanced or metastatic solid tumors

Oxford Immunotec Global PLC announced that it has been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by the UK Government to assess the suitability of vaccines for use in the UK population.

The Institute for Quantitative Health Science and Engineering at Michigan State University and Leica Microsystems, Inc., have combined efforts to establish the MSU IQ Leica Microsystems Center of Excellence.

Abcam plc, a global leader in the supply of life science research tools, announces the pricing of its offering of 8,945,218 American Depositary Shares, representing an aggregate of 8,945,218 ordinary shares, at a price of $17.50 per ADS, for aggregate proceeds of approximately $156.5 million, before deducting underwriting discounts and commissions.

Longevity Acquisition Corporation, a publicly-traded special purpose acquisition company, announced that it has signed a definitive merger agreement with 4D pharma PLC.